Pyrroloquinoline Quinone (PQQ): a novel approach to managing chronic inflammatory response syndrome and mitochondrial dysfunction

Abstract

Chronic Inflammatory Response Syndrome (CIRS) is a complex, multi-system condition associated with persistent inflammation in response to biotoxins like mould or other environmental triggers. Mitochondrial dysfunction has been implicated in the pathophysiology of CIRS, contributing to chronic inflammation and exacerbating symptoms. Pyrroloquinoline quinone (PQQ), a redox cofactor, has gained attention for its potential neuroprotective, anti-inflammatory, and mitochondria-supporting properties. Additionally, CIRS shares overlapping features with cytokine storm effects observed in COVID infection, long COVID, and potential inflammatory reactions related to mRNA vaccine administration. This letter explores the role of PQQ in managing CIRS and addressing mitochondrial dysfunction caused by multiple potential triggers. However, further research is needed to confirm the effectiveness and safety of PQQ in addressing CIRS and related conditions.